Company intelligence / Profile preview
CellVax Therapeutics
Miami, Florida, United Statescellvx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
CellVax Therapeutics has dosed the first patient in a randomized Phase 2 clinical trial for FK-PC101, a novel personalized cancer immunotherapy for prostate cancer patients with high risk of recurrence after prostatectomy[3].
- Therapeutic areas
- OncologyRheumatology
- Modalities
- Cell-based immunotherapyAutologous cancer vaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Theragent Inc. (CDMO partner)BIOBANQUES (French national organization)Strategic partnerships with Chinese CROs
Beyond the preview
Go deeper on CellVax Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellVax Therapeutics.